OPK Biotech LLC develops, manufactures and markets oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body’s tissues. Using our patented and proprietary technology, we have developed and manufacture two products: Hemopure® (HBOC-201) [hemoglobin glutamer – 250 (bovine)] for human use, and Oxyglobin® (HBOC-301) [hemoglobin glutamer – 200 (bovine)] for veterinary use.
Oxyglobin, for the treatment of all-cause anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration (FDA) and the European Commission. Approximately, 200,000 units have been sold.
The Company operates manufacturing facilities in Cambridge, Massachusetts and Souderton Pennsylvania.
OPK Biotech 